Blends
BPC-157 / TB blend
What is it?
This attachment lists two blends containing equal stated masses of BPC and TB material. The components are presented as BPC-157 and TB-500 / thymosin beta-4-related entries elsewhere in the document. Exact identities must still be confirmed rather than inferred from abbreviated blend names.
How it is studied
The research rationale combines different tissue-response pathways. BPC-associated cellular studies and thymosin beta-4-related migration biology concern different experimental materials. Combining them is a separate formulation and biological question.
What the evidence shows
The linked BPC explant/cell study and thymosin beta-4 ophthalmic trial provide component context only. Neither evaluates BB10 or BB20. Evidence for a cell response or an eye-drop preparation does not establish a beneficial interaction in this supplier blend.
Limitations & safety context
The attachment states ratios but does not supply blend-specific stability, sequence or analytical data. Total and component masses do not prove healing, systemic efficacy or safety. TB material may differ in sequence from the thymosin beta-4 used in a published study.
Listed specifications
| Reference | Listed contents |
|---|---|
| BB10 | 5 mg BPC + 5 mg TB |
| BB20 | 10 mg BPC + 10 mg TB |
Source-document quantities, not doses or a confirmation of stock. Identity, purity, component composition and suitability require separate documentation.
Research information only. No dosing, administration or treatment advice.